Clinical Trial Update: Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension [Phase 2]

View source ↗

Summary

Phase 2 trial update determined the optimal dose of AD-209 in patients with essential hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• AD-209

Snippet

Sponsor: Addpharma Inc. | Conditions: Hypertension,Essential | Phase 2 | Status: COMPLETED